BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 33945400)

  • 1. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
    Budel SJ; Penning MM; Penning LC
    Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary investigation of the role of the transcription co-activators YAP/TAZ of the Hippo signalling pathway in canine and feline mammary tumours.
    Beffagna G; Sacchetto R; Cavicchioli L; Sammarco A; Mainenti M; Ferro S; Trez D; Zulpo M; Michieletto S; Cecchinato A; Goldschmidt M; Zappulli V
    Vet J; 2016 Jan; 207():105-111. PubMed ID: 26626094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury.
    Konishi T; Schuster RM; Lentsch AB
    Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G471-G482. PubMed ID: 29351389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research advances in the role of the Hippo-YAP/TAZ signaling pathway in primary liver cancer].
    Guo LW; Shao GL
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):878-880. PubMed ID: 29325286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the Hippo signalling effectors YAP and TAZ in canine mammary gland hyperplasia and malignant transformation of mammary tumours.
    Rico C; Boerboom D; Paquet M
    Vet Comp Oncol; 2018 Dec; 16(4):630-635. PubMed ID: 30117264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
    Nishina H
    Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.
    Shi H; Zou Y; Zhong W; Li Z; Wang X; Yin Y; Li D; Liu Y; Li M
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15311-15322. PubMed ID: 37608027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt/β-Catenin and Hippo Pathway Deregulation in Mammary Tumors of Humans, Dogs, and Cats.
    Sammarco A; Gomiero C; Sacchetto R; Beffagna G; Michieletto S; Orvieto E; Cavicchioli L; Gelain ME; Ferro S; Patruno M; Zappulli V
    Vet Pathol; 2020 Nov; 57(6):774-790. PubMed ID: 32807036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hippo signaling in regeneration and aging.
    Elster D; von Eyss B
    Mech Ageing Dev; 2020 Jul; 189():111280. PubMed ID: 32512018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis.
    Patel SH; Camargo FD; Yimlamai D
    Gastroenterology; 2017 Feb; 152(3):533-545. PubMed ID: 28003097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of signaling pathways regulating YAP/TAZ activity.
    Heng BC; Zhang X; Aubel D; Bai Y; Li X; Wei Y; Fussenegger M; Deng X
    Cell Mol Life Sci; 2021 Jan; 78(2):497-512. PubMed ID: 32748155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the transcriptional coactivators YAP/TAZ in liver cancer.
    Zhang S; Zhou D
    Curr Opin Cell Biol; 2019 Dec; 61():64-71. PubMed ID: 31387016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.
    Moya IM; Castaldo SA; Van den Mooter L; Soheily S; Sansores-Garcia L; Jacobs J; Mannaerts I; Xie J; Verboven E; Hillen H; Algueró-Nadal A; Karaman R; Van Haele M; Kowalczyk W; De Waegeneer M; Verhulst S; Karras P; van Huffel L; Zender L; Marine JC; Roskams T; Johnson R; Aerts S; van Grunsven LA; Halder G
    Science; 2019 Nov; 366(6468):1029-1034. PubMed ID: 31754005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine.
    Moya IM; Halder G
    Nat Rev Mol Cell Biol; 2019 Apr; 20(4):211-226. PubMed ID: 30546055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
    Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
    J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hippo pathway in normal development and cancer.
    Maugeri-Saccà M; De Maria R
    Pharmacol Ther; 2018 Jun; 186():60-72. PubMed ID: 29305295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.
    Liu Y; Wang X; Yang Y
    Clin Mol Hepatol; 2020 Oct; 26(4):742-750. PubMed ID: 32981290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.